MarketBeat
24 Oct 2026, 02:02 UTC · 1h ago
Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity
Impact · against what's priced in
Novartis sees a significant growth catalyst in remibrutinib following positive Phase III results in relapsing MS, unlocking a projected $4 billion peak sales opportunity. The use of a priority review voucher and the lack of a liver safety signal further derisk the path to a 2027 launch without restrictive monitoring.
- NVS+0.70
No priced-in read yet
- In context
Phase III results show remibrutinib reduced annualized relapse rates by 35% and 31.2% in two studies, supporting a $4 billion peak sales projection. The use of a priority review voucher for the U.S. filing and the absence of a liver safety signal facilitate a faster, cleaner market entry.
Read from the article alone
